SCHEMBL14531990

SCHEMBL14531990

CN1CCOCCC(C)(C)C1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.34
KDM4E B2RXH2 2/20 0.34
GAA P10253 2/20 0.34
ALDH1A1 P00352 4/20 0.33
GLA P06280 1/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
MAPT P10636 1/20 0.32
KEAP1 Q14145 1/20 0.31
CA12 O43570 1/20 0.31
CA7 P43166 1/20 0.31
CA14 Q9ULX7 1/20 0.31
LMNA P02545 1/20 0.31
TSHR P16473 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
PIK3R1 P27986 2/20 0.30
PIK3CA P42336 2/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24928031 0.79
SCHEMBL18085492 0.78 GAA (0.36) L3MBTL1KDM4EGAAALDH1A1GLA
SCHEMBL254577 0.75
SCHEMBL12946059 0.71 MGLL (0.31)
SCHEMBL1221354 0.71
SCHEMBL20614479 0.71 CA12 (0.45) L3MBTL1KDM4EALDH1A1GLASMN1; SMN2
SCHEMBL10001930 0.71 CA12 (0.45) L3MBTL1KDM4EALDH1A1GLASMN1; SMN2
SCHEMBL2123718 0.71 CA12 (0.45) L3MBTL1KDM4EALDH1A1GLASMN1; SMN2
SCHEMBL684388 0.71
SCHEMBL4622 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021071812-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed
WO-2007054550-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-18 WO disclosed
WO-2007054551-A1 COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-18 WO disclosed